No pharmacy in the United States can fill a Simtriyo prescription yet, and the reason has nothing to do with manufacturing or insurance. The Drug Enforcement Administration has not yet decided how tightly the drug will be controlled.
Otsuka's newly approved ADHD capsule is classified in its own label as a central nervous system stimulant, and federal law requires the DEA to assign a controlled substance schedule before a stimulant can be dispensed. That review is a standard step for all newly approved CNS stimulants and can take up to three months. Otsuka has said only that it expects the drug to be available later this year.
The schedule the DEA lands on will do more than set a date. It will determine how many pills a prescription can cover, whether refills are permitted, and how often a family has to return to a prescriber.
One Correction Worth Making Up Front
Much early coverage of centanafadine, including MedicalDaily's own, described it as a non-stimulant option for patients who could not tolerate traditional stimulants. The approved label does not support that description.
The prescribing information identifies Simtriyo as a norepinephrine-dopamine-serotonin reuptake inhibitor and a CNS stimulant, and it carries a boxed warning for abuse, misuse, and addiction. It is a novel stimulant with a mechanism no previously approved ADHD drug uses, which is genuinely new. It is not a non-stimulant.
The distinction is not academic for families. Non-stimulants such as atomoxetine and guanfacine are not controlled substances, can be prescribed with routine refills, and are often chosen precisely to avoid the monthly pharmacy cycle that stimulant prescriptions require. Simtriyo will not offer that.
What the DEA Schedule Will Actually Change
Scheduling is the difference between a prescription that behaves like most medications and one that behaves like Adderall.
A Schedule II designation, which covers amphetamine and methylphenidate products including Adderall and Vyvanse, prohibits refills. Each month requires a new prescription. Quantities are typically limited to a 30-day supply, transferring a prescription between pharmacies is restricted, and a pharmacy that is out of stock cannot simply have another fill it. Families who manage stimulant prescriptions already know this rhythm.
A less restrictive schedule would loosen most of that. Schedule IV drugs, for instance, permit refills and are far easier to manage across a school year.
Jefferies analysts wrote in a July 26 note that the classification could shape the drug's commercial trajectory, observing that "The ADHD market remains large and under-penetrated" and that a lower schedule could position Simtriyo between traditional stimulants and non-stimulants. That is an investment view rather than a clinical one, and it should be read as such, but it describes the access reality accurately: schedule drives convenience, and convenience drives whether people stay on treatment.
Otsuka has said the final classification is not yet clear. No one, including the company, can currently tell a parent what the refill rules will be.
The Two Boxed Warnings Parents Should Read First
Before any conversation about timing, the label carries two boxed warnings, the FDA's most serious form of prescribing caution.
The first concerns suicidal ideation and behaviors in pediatric patients aged 6 and older. According to the label, higher rates of suicidal ideation and behaviors occurred in Simtriyo-treated patients aged 6 to 12 with ADHD than in patients receiving placebo. The label instructs prescribers to "Closely monitor all pediatric patients for suicidal ideation and behaviors" and to consider stopping the drug in patients who develop them. That warning applies to the youngest group the drug is approved for.
The second concerns abuse, misuse, and addiction. The label states that abuse of CNS stimulants can lead to substance use disorder, and that misuse and abuse can result in overdose and death. It directs prescribers to assess each patient's risk before prescribing and to educate families about proper storage and disposal.
Additional labeled warnings include increased blood pressure and heart rate, long term suppression of growth in children, new psychotic or manic symptoms, serotonin syndrome when combined with other serotonergic drugs, peripheral vasculopathy including Raynaud's phenomenon, and emergence or worsening of tics and Tourette's syndrome. The drug is contraindicated in patients taking a monoamine oxidase inhibitor or within 14 days of stopping one, and in patients with pheochromocytoma. The label advises avoiding it in patients with serious cardiac disease.
Reported adverse reactions differ by age. In children 6 to 12, they were rash and decreased appetite. In adolescents 13 to 17, they were decreased appetite, nausea, rash, headache, and abdominal pain. In adults, they were headache, decreased appetite, insomnia, nausea, dry mouth, and diarrhea.
None of this means the drug is unsafe or should be avoided. It means the decision belongs in a clinical conversation, and that a parent reading about a new option should walk into that conversation already knowing what the boxed warnings say.
What Families Can Reasonably Do Now, and What to Skip
There is no way to secure a supply in advance, so effort is better spent on preparation.
A useful conversation with a prescriber covers whether a new mechanism is even indicated for this particular child or adult, what has already been tried and how it failed, cardiac history and any family history of sudden cardiac events, current medications that act on serotonin, and any history of tics, psychosis, or mania. Growth monitoring matters for children, so recent height and weight are worth having on hand. The weight threshold is a hard eligibility line: the label covers patients 6 and older weighing at least 20 kilograms, roughly 44 pounds, and specifically does not recommend use below that weight.
On cost, no verified pricing, formulary placement, or patient assistance program for Simtriyo has been published. Anyone told otherwise should treat that as unconfirmed. Once the product launches, the practical steps are checking the insurer's formulary, asking whether prior authorization applies, and asking the prescriber's office about manufacturer support programs then rather than now.
What to skip: do not stop, reduce, or change an existing ADHD medication in anticipation of switching. Do not attempt to buy centanafadine from an online seller. A drug awaiting DEA scheduling is not legally available in the United States, so anything marketed as Simtriyo right now is not what it claims to be.
If a child or adult already taking an ADHD medication is experiencing new suicidal thoughts, contact the prescribing clinician promptly, and seek urgent care for immediate safety concerns. The 988 Suicide and Crisis Lifeline is available by call or text at any hour.
What Happens Next
The next verifiable milestone is the DEA's scheduling decision, expected within roughly three months of approval. Otsuka has said commercial availability follows. Full results from a completed Phase 3b study in adults with ADHD and comorbid anxiety have not yet been presented at a scientific meeting and are not peer reviewed, so they should not be treated as established findings.
Longer-term durability is also unresolved. The pivotal adult trials measured outcomes over six weeks, which says little about how the drug performs across years of treatment.
The bottom line: Simtriyo is approved but cannot be dispensed until the DEA assigns it a controlled substance schedule, a decision that will govern refills and monthly logistics. Families of children 6 and older weighing at least 20 kilograms who have not done well on existing medications are the group most affected. The reasonable step now is a clinician conversation informed by the two boxed warnings, not an attempt to obtain the drug. The central uncertainty is the schedule itself.
Frequently Asked Questions
When can I fill a Simtriyo prescription? Not yet. The DEA must assign a controlled substance schedule first, a review that can take up to three months. Otsuka expects availability later in 2026 but has not given a date.
Is Simtriyo a stimulant or a non-stimulant? Its label identifies it as a central nervous system stimulant with a novel mechanism. Earlier reporting, including some of MedicalDaily's, described it as a non-stimulant. That was inaccurate.
Why does the schedule matter to me? It determines refills and quantity limits. A Schedule II designation would mean a new prescription every month with no refills, like Adderall. A lower schedule would allow refills.
Who is eligible under the label? Adults and children 6 years and older weighing at least 20 kilograms, about 44 pounds. Use is not recommended below age 6 or below 20 kilograms.
What are the boxed warnings? Higher rates of suicidal ideation and behaviors in treated patients aged 6 to 12 compared with placebo, and the risk of abuse, misuse, and addiction as a CNS stimulant.
What will it cost? No verified price, formulary placement, or patient assistance program has been published. Check with your insurer and prescriber after launch.
Should I switch my child from their current medication? That is a decision for a qualified clinician. Do not stop or change any prescribed ADHD medication based on a news article.
Can I buy it online now? No. Anything sold as Simtriyo before DEA scheduling is not a legitimate product.
